Evidence map›Paper›PMID 29411162›Full record

ArticleClinical and experimental nephrology2018

Ensuring safe drug administration to pediatric patients with renal dysfunction: a multicenter study.

Ryoko Harada, Kenji Ishikura, Shunsuke Shinozuka, Naoaki Mikami, Riku Hamada, Hiroshi Hataya, Yoshihiko Morikawa, Tae Omori, Hirotaka Takahashi, Yuko Hamasaki and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Highly pathogenic coronaviruses and the kidney.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Ryoko HaradaDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Kenji IshikuraDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan. kenzo@ii.e-mansion.com.
Shunsuke ShinozukaDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Naoaki MikamiDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Riku HamadaDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Hiroshi HatayaDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Yoshihiko MorikawaClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Tae OmoriDepartment of Pediatrics, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Hirotaka TakahashiDepartment of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Yuko HamasakiDepartment of Pediatric Nephrology, Toho University Faculty of Medicine, Tokyo, Japan.
Tetsuji KanekoClinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Kazumoto IijimaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Masataka HondaDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Tokyo Metropolitan Children's Medical Center · JPKobe University · JPToho University · JPTokyo-Kita Medical Center · JPTokyo Metropolitan Bokutoh Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn pediatric patients, due to variations in baseline serum creatinine (Cr) reference values, renal dysfunctions sometimes go unnoticed. In addition, renally excreted drugs need dose adjustment while nephrotoxic drugs should be avoided altogether in patients with impaired renal function. However, most physicians are apparently unaware of these facts and may administer these drugs to vulnerable patients.

methodsWe administered a questionnaire to all physicians and pharmacists specializing in pediatric medical care at six Tokyo metropolitan government-run hospitals in Japan.

results276 (59%) of 470 physicians and pharmacists participated. The rate of correct answers given by physicians who were asked to state the serum Cr reference range for 4-year-olds and 8-year-olds was 83 and 74%, respectively. On the other hand, the rate of correct answers given by pharmacists to the same question was only 27 and 24%, respectively. Only about 50% of physicians were aware that histamine H

conclusionsFor the majority of the investigated drugs, the awareness that we need to reduce dosages for patients with renal dysfunction was insufficient. To ensure safe drug administration, communication between physicians and pharmacists is paramount. There is an urgent need for the creation of a safe drug administration protocol for pediatric patients with renal dysfunction.

Indexed as

Drug-Related Side Effects and Adverse ReactionsChildCreatinineHumansJapanKidneyPharmaceutical PreparationsSurveys and QuestionnairesTokyoCreatininePharmaceutical PreparationsAcute kidney injury (AKI)ChildrenChronic kidney disease (CKD)Nephrotoxic drugsRenal dysfunctionRenally excreted drugs

Identifiers

PMID29411162
OpenAlexW2789687728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.